About Us
Fastenate Technologies is focused on solving the challenges of bioprocessing and biopharmaceutical manufacturing with ground-breaking optical-based biophysical technologies.
We’re a spin-off of NanoTemper Technologies, known for creating first-of-kind technology to advance the research and development of small molecule and biologics-based therapies. At Fastenate, we’re expanding our reach into bioprocessing and biopharmaceutical manufacturing, applying our expertise and know-how from our experience at NanoTemper, to solve some of the industry’s toughest challenges — ultimately changing the way things are done.
As therapies become more complex, the need arises for new tools to handle the processing and manufacturing of them. It is our mission to create ground-breaking technologies to enable the production of these difficult-to-produce therapies, moving one step closer to our vision of creating a world where every disease is treatable.
We know that we can’t achieve this vision on our own and partnering with scientists, researchers, and engineers is so important. If you believe in our vision and are interested in pursuing a collaboration or partnership, we’d love to hear from you.
Board
Oliver Klaeffling
Oliver Klaeffling is the Managing Director of Analytik Jena, a supplier of high-end analytical instrumentation and products in the field of biotechnology and molecular diagnostics, as well as high-class liquid handling and automation technology.
Prior to his current role, Oliver Klaeffling worked in various leadership at Merck Life Science for 18 years. During this time Mr. Klaeffling lived in Boston for four years where he led Merck Millipore's Integrated Pharm Solutions and Millipore Sigma's Upstream and Systems business units. He was in charge of all Bioprocess unit operations, cell culture media, and media-related chemicals and additives. Together with his team, Mr. Klaeffling developed and successfully launched many innovative products including the bioreactor, mixer, and filtration product lines. Most recently he led the Merck Innovation Center in Darmstadt, Germany.
Prior to Merck, Mr. Klaeffling worked in plant engineering and chemical custom synthesis companies. He started his career with Roland Berger's chemicals consulting practice in Düsseldorf.
He holds a degree in Technical Chemistry and Business Administration (Wirtschaftsingenieur) from Technische Universität Berlin.
Dr. Ing.-habil. Michael Pohlscheidt
Dr. Ing.-habil. Michael Pohlscheidt, a German National, holds a Ph.D. in Bioprocess Engineering from the University of Magdeburg, Germany, where he successfully concluded his habilitation in 2014. In addition, Michael completed an EMBA in International Supply Chain Management at ETH Zurich, Switzerland 2010.
Michael has a broad background in the life science and biotech industry. He started his career in 2002 at Bayer HealthCare, where he first worked as a scientist in the biotech process development department before he joined Roche in 2005 in the Pharma Biotech Production site in Penzberg, Germany. He held various leadership roles within Roche in the area of process development, biotech manufacturing, supply chain management, and external manufacturing operations across different geographies in Europe, the United States, and South Korea. In 2017, he joined Biogen as the GM and Site Head accountable for the construction and start-up of a $1.5B manufacturing facility in Solothurn, Switzerland.
In 2020, Michael joined DSM as Global VP of Global Premix & Additive Operations. In this role, he transformed the organization towards a world-class operations team with an emphasis on automation, digitalization, and operational excellence, driving quality, safety, and customer satisfaction. Since July, Michael assumed the role of COO, Head of Supply and Commercial Operations as part of the Animal Nutrition and Health Leadership Team. In this function, Michael and his team ensure demand fulfillment end to end including supply chain, manufacturing operations, digital & virtual sales solutions, commercial optimization, and customer-enabling services (e.g. analytics, quality services, formulation, etc.).